The impact of the IRA on us and the pharmaceutical industry cannot yet be fully determined, but is likely to be significant.
All entries for: Endocrinology
May 11, 2026
Sana Biotechnology, Inc.
Negative Outlook
Seattle, Washington
51-200 employees
If we obtain regulatory approval for any of our product candidates, the IRA could substantially and negatively impact the prices we may charge for such products, which could harm our ability to generate revenue and achieve and sustain profitability.
Disease Area: Endocrinology, Hematology, Immune Diseases, Oncology
Drug Type: Biologic
April 29, 2026
NewcelX Ltd.
Neutral Outlook
Kloten, Switzerland
1-50 employees
It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry.
Disease Area: Endocrinology, Neurological Diseases
Drug Type: Small Molecule
April 15, 2026
CDT Equity Inc.
Neutral Outlook
Among other things, the IRA has multiple provisions that can impact the prices of drug products that are both sold into the Medicare program and throughout the United States.
Disease Area: Endocrinology, Immune Diseases, Metabolic Diseases
April 1, 2026
Novo Nordisk
Layoffs
Bagsværd
10,000+ employees
Novo Nordisk will part ways with around 400 employees at its manufacturing site in Bloomington, Indiana, as part of a broader restructuring initiative, Fierce Pharma revealed in a March 31 report, confirming the news with a company spokesperson.
The layoffs will take effect “at the beginning of May,” the spokesperson added, noting that after the cuts, the production plant will be down to approximately 1,400 employees.
The Bloomington facility came to Novo as part of a larger deal by the pharma’s parent company, Novo Holdings, to acquire the CDMO giant Catalent in early 2024 for $16.5 billion. The site, however, has since become a source of headache for Novo, with the FDA flagging persistent contaminations and infestations. These violations have resulted in the rejection of several drugs, including from Incyte, Scholar Rock and Regeneron.
Novo announced a sweeping reorganization effort in September 2025, involving 9,000 layoffs across its global operations. Headcount reduction cycles that followed in the U.S. include one affecting 263 people in New Jersey late last year and another impacting 47 employees in North Carolina in October 2025.
Disease Area: Cardiovascular, Endocrinology, Metabolic Diseases, Multiple
Drug Type: Biologic, Small Molecule
March 27, 2026
Entera Bio Ltd
Neutral Outlook
Jerusalem, Israel
1-50 employees
Further, on August 16, 2022, Congress enacted the Inflation Reduction Act allowing CMS to negotiate directly with drug manufacturers to lower the price of some of the costliest drugs under the Medicare program, as well as requiring drug manufacturers to provide Medicare with a rebate if the price of drugs increases faster than the rate of inflation.
Disease Area: Endocrinology, Metabolic Diseases
Drug Type: Biologic